Average Insider

Where insiders trade, we follow

Insider Buy/Sell Details for the Biotechnology Industry — February 2026

Extreme outlier transactions (>3σ) are excluded.Show All Data
Ratio0.1:1
Daily Buy & Sell Volume

ONCOLYTICS BIOTECH INC (ONCY)

Hagerman Allison — VP, Product Development
Feb 12, 2026
Purchase
Shares
10,000
Price
$0.83
Total Value
$8.30K
Shares Held After
115,059
% of Holdings
8.7%
Feb 12, 2026
Purchase
Shares
40,000
Price
$0.85
Total Value
$33.86K
Shares Held After
566,991
% of Holdings
7.1%

ONCOLYTICS BIOTECH INC (ONCY)

Look Kirk — Chief Financial Officer
Feb 12, 2026
Purchase
Shares
12,000
Price
$0.84
Total Value
$10.10K
Shares Held After
287,515
% of Holdings
4.2%

ONCOLYTICS BIOTECH INC (ONCY)

Heineman Thomas Charles — Chief Medical Officer
Feb 12, 2026
Purchase
Shares
12,132
Price
$0.83
Total Value
$10.03K
Shares Held After
282,818
% of Holdings
4.3%
Feb 12, 2026
Purchase
Shares
25,000
Price
$0.85
Total Value
$21.24K
Shares Held After
109,851
% of Holdings
22.8%
Feb 12, 2026
Purchase
Shares
30,000
Price
$0.84
Total Value
$25.34K
Shares Held After
492,414
% of Holdings
6.1%
Feb 12, 2026
Purchase
Shares
29,500
Price
$0.84
Total Value
$24.84K
Shares Held After
109,000
% of Holdings
27.1%

RHYTHM PHARMACEUTICALS, INC. (RYTM)

Smith Hunter C — Chief Financial Officer
Feb 12, 2026
Sale
Shares
100
Price
$100.10
Total Value
$10.01K
Shares Held After
118,466
% of Holdings
0.1%

RHYTHM PHARMACEUTICALS, INC. (RYTM)

Smith Hunter C — Chief Financial Officer
Feb 12, 2026
Sale
Shares
800
Price
$98.99
Total Value
$79.19K
Shares Held After
118,566
% of Holdings
0.7%

RHYTHM PHARMACEUTICALS, INC. (RYTM)

Smith Hunter C — Chief Financial Officer
Feb 12, 2026
Sale
Shares
400
Price
$97.67
Total Value
$39.07K
Shares Held After
119,366
% of Holdings
0.3%

RHYTHM PHARMACEUTICALS, INC. (RYTM)

Smith Hunter C — Chief Financial Officer
Feb 12, 2026
Sale
Shares
292
Price
$96.26
Total Value
$28.11K
Shares Held After
119,766
% of Holdings
0.2%
Shares
2,690
Price
$45.00
Total Value
$121.05K
Shares Held After
12,546
% of Holdings
17.7%
Feb 11, 2026
Sale
Shares
425,000
Price
$26.67
Total Value
$11.33M
Shares Held After
15,928,113
% of Holdings
2.6%
Feb 11, 2026
Sale
Shares
425,000
Price
$26.67
Total Value
$11.33M
Shares Held After
15,928,113
% of Holdings
2.6%

Roivant Sciences Ltd. (ROIV)

QVT Financial LP — Director by Deputization
Feb 11, 2026
Sale
Shares
425,000
Price
$26.67
Total Value
$11.33M
Shares Held After
15,928,113
% of Holdings
2.6%
Feb 11, 2026
Sale
Shares
955
Price
$64.99
Total Value
$62.07K
Shares Held After
1,172,987
% of Holdings
0.1%
Feb 11, 2026
Sale
Shares
7,551
Price
$63.73
Total Value
$481.23K
Shares Held After
1,173,942
% of Holdings
0.6%
Feb 11, 2026
Sale
Shares
11,494
Price
$62.96
Total Value
$723.66K
Shares Held After
1,181,493
% of Holdings
1.0%
Feb 11, 2026
Sale
Shares
5,000
Price
$82.72
Total Value
$413.59K
Shares Held After
56,344
% of Holdings
8.2%

Zenas BioPharma, Inc. (ZBIO)

Lu Hongbo — Director
Feb 11, 2026
Purchase
Shares
25,985
Price
$22.50
Total Value
$584.66K
Shares Held After
347,968
% of Holdings
7.5%

Contineum Therapeutics, Inc. (CTNM)

Lorrain Daniel S. — Chief Scientific Officer
Feb 11, 2026
Sale
Shares
400
Price
$16.00
Total Value
$6.40K
Shares Held After
156,052
% of Holdings
0.3%
Feb 11, 2026
Sale
Shares
400
Price
$16.00
Total Value
$6.40K
Shares Held After
14,954
% of Holdings
2.6%

Neuraxis, INC (NRXS)

Hannasch Brian — 10% Owner
Feb 11, 2026
Purchase
Shares
40,000
Price
$4.65
Total Value
$186.00K
Shares Held After
1,171,522
% of Holdings
3.4%

AnaptysBio, Inc. (ANAB)

LOUMEAU ERIC J — CHIEF LEGAL OFFICER
Feb 11, 2026
Sale
Shares
10,000
Price
$54.00
Total Value
$540.00K
Shares Held After
12,835
% of Holdings
43.8%

Vericel Corp (VCEL)

MCLAUGHLIN KEVIN F — Director
Feb 11, 2026
Sale
Shares
7,000
Price
$34.66
Total Value
$242.62K
Shares Held After
15,100
% of Holdings
31.7%
Feb 11, 2026
Purchase
Shares
8,881
Price
$23.57
Total Value
$209.37K
Shares Held After
650,563
% of Holdings
1.4%
Feb 11, 2026
Purchase
Shares
8,882
Price
$23.57
Total Value
$209.39K
Shares Held After
650,567
% of Holdings
1.4%

Apellis Pharmaceuticals, Inc. (APLS)

DeLong Mark Jeffrey — Chief Business & Strat Officer
Feb 11, 2026
Sale
Shares
368
Price
$22.15
Total Value
$8.15K
Shares Held After
114,591
% of Holdings
0.3%

ONCOLYTICS BIOTECH INC (ONCY)

Aromando Andrew — Chief Business Officer
Feb 11, 2026
Purchase
Shares
29,600
Price
$0.86
Total Value
$25.42K
Shares Held After
55,100
% of Holdings
53.7%
Feb 11, 2026
Purchase
Shares
60,000
Price
$0.83
Total Value
$49.59K
Shares Held After
526,991
% of Holdings
11.4%
Feb 11, 2026
Purchase
Shares
5,600
Price
$0.84
Total Value
$4.68K
Shares Held After
79,500
% of Holdings
7.0%

Lyell Immunopharma, Inc. (LYEL)

Lee Gary K. — Chief Scientific Officer
Feb 11, 2026
Sale
Shares
1,671
Price
$23.39
Total Value
$39.08K
Shares Held After
16,938
% of Holdings
9.0%

Lyell Immunopharma, Inc. (LYEL)

Hill Stephen J. — Chief Operating Officer
Feb 11, 2026
Sale
Shares
1,236
Price
$23.39
Total Value
$28.91K
Shares Held After
17,795
% of Holdings
6.5%
Feb 11, 2026
Sale
Shares
7,455
Price
$23.39
Total Value
$174.37K
Shares Held After
74,266
% of Holdings
9.1%

RHYTHM PHARMACEUTICALS, INC. (RYTM)

Smith Hunter C — Chief Financial Officer
Feb 11, 2026
Sale
Shares
100
Price
$100.85
Total Value
$10.09K
Shares Held After
120,058
% of Holdings
0.1%

RHYTHM PHARMACEUTICALS, INC. (RYTM)

Smith Hunter C — Chief Financial Officer
Feb 11, 2026
Sale
Shares
400
Price
$99.44
Total Value
$39.77K
Shares Held After
120,158
% of Holdings
0.3%

RHYTHM PHARMACEUTICALS, INC. (RYTM)

Smith Hunter C — Chief Financial Officer
Feb 11, 2026
Sale
Shares
2,266
Price
$98.37
Total Value
$222.91K
Shares Held After
120,558
% of Holdings
1.8%
Feb 11, 2026
Sale
Shares
241
Price
$18.00
Total Value
$4.34K
Shares Held After
351,370
% of Holdings
0.1%

VERTEX PHARMACEUTICALS INC / MA (VRTX)

Tatsis Ourania — EVP, Chief Reg. & Quality Off.
Feb 11, 2026
Sale
Shares
466
Price
$460.43
Total Value
$214.56K
Shares Held After
51,436
% of Holdings
0.9%
Feb 11, 2026
Sale
Shares
2,151,458
Price
$0.68
Total Value
$1.46M
Shares Held After
2,651,817
% of Holdings
44.8%
Feb 11, 2026
Sale
Shares
1,905,115
Price
$0.68
Total Value
$1.30M
Shares Held After
2,348,183
% of Holdings
44.8%
Feb 11, 2026
Sale
Shares
3,961
Price
$73.25
Total Value
$290.15K
Shares Held After
4,478,447
% of Holdings
0.1%
Feb 11, 2026
Sale
Shares
4,404
Price
$72.65
Total Value
$319.94K
Shares Held After
4,482,408
% of Holdings
0.1%
Feb 11, 2026
Sale
Shares
3,775
Price
$71.46
Total Value
$269.75K
Shares Held After
4,486,812
% of Holdings
0.1%
Feb 11, 2026
Sale
Shares
7,860
Price
$70.70
Total Value
$555.71K
Shares Held After
4,490,587
% of Holdings
0.2%
Feb 11, 2026
Sale
Shares
3,994
Price
$73.25
Total Value
$292.57K
Shares Held After
675,686
% of Holdings
0.6%
Feb 11, 2026
Sale
Shares
4,484
Price
$72.64
Total Value
$325.70K
Shares Held After
679,680
% of Holdings
0.7%
Feb 11, 2026
Sale
Shares
3,716
Price
$71.44
Total Value
$265.48K
Shares Held After
684,164
% of Holdings
0.5%
Feb 11, 2026
Sale
Shares
7,806
Price
$70.69
Total Value
$551.80K
Shares Held After
687,880
% of Holdings
1.1%

VERTEX PHARMACEUTICALS INC / MA (VRTX)

Ambrose Kristen — SVP & Chief Accounting Officer
Feb 11, 2026
Sale
Shares
1,376
Price
$460.43
Total Value
$633.55K
Shares Held After
10,127
% of Holdings
12.0%
Version: v26.3.29